Shares of Rallybio Co. (NASDAQ:RLYB – Get Free Report) have been given an average recommendation of “Moderate Buy” by the six brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $10.00.
A number of research analysts have commented on RLYB shares. Evercore ISI reissued an “outperform” rating and set a $15.00 target price on shares of Rallybio in a research report on Monday, August 26th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Rallybio in a research report on Tuesday, October 1st.
Rallybio Price Performance
Rallybio (NASDAQ:RLYB – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. The company had revenue of $0.30 million during the quarter. Sell-side analysts forecast that Rallybio will post -1.45 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Hsbc Holdings PLC acquired a new stake in Rallybio in the 2nd quarter worth approximately $25,000. Acadian Asset Management LLC acquired a new stake in Rallybio in the 1st quarter worth approximately $57,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Rallybio in the 2nd quarter worth approximately $61,000. Almitas Capital LLC acquired a new stake in Rallybio in the 2nd quarter worth approximately $135,000. Finally, Vanguard Group Inc. boosted its stake in Rallybio by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 1,076,771 shares of the company’s stock worth $1,992,000 after purchasing an additional 12,801 shares in the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.
Rallybio Company Profile
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
Read More
- Five stocks we like better than Rallybio
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Survey Reveals: America’s Most Coveted Businesses in 2024
- CD Calculator: Certificate of Deposit Calculator
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Buy Cheap Stocks Step by Step
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.